Citigroup analyst Geoff Meacham has identified Vertex Pharmaceuticals as his top biotech pick after the company finalized its acquisition of Crinetics Pharmaceuticals, a deal valued at $10 billion in equity or $8.8 billion net of acquired cash. Meacham’s note emphasizes the strategic importance of the transaction for Vertex and flags the expanded therapeutic focus that the company now carries into its commercial and clinical portfolio.
The deal closed after Vertex obtained regulatory clearance and secured shareholder approval. Immediate commercial revenue is expected from PALSONIFY, which is described as the first and only once-daily oral therapy approved for acromegaly. Citigroup projects PALSONIFY sales of $700 million by 2030 and notes additional upside potential tied to atumelnant, a clinical-stage program acquired through Crinetics.
Atumelnant remains in development across multiple indications: it is in phase 3 for congenital adrenal hyperplasia and in phase 2 for Cushing’s syndrome. Those pipeline assets, combined with the PALSONIFY commercial launch, position endocrinology as a new strategic pillar alongside Vertex’s established franchises in cystic fibrosis, hematology, pain, and renal.
Citigroup has retained a Buy rating on Vertex and set a $585 price target. The firm’s analysis assumes the company will disclose comprehensive financial details related to the transaction on Vertex’s third quarter 2026 earnings call on November 2. Vertex continues to expect the acquisition to be accretive to non-GAAP operating income in 2029.
Management changes tied to the integration were also announced. Charles Wagner will immediately take on responsibility for the Crinetics integration as part of an expanded Chief Operating Officer role. Jonathan Poole, currently Senior Vice President Finance, is slated to become Chief Financial Officer on January 1, 2027. In addition, Jasper van Grunsven will join Vertex as Executive Vice President, Chief Pain and New Product Planning Officer on September 8.
Market recognition of Vertex’s strategic move extended beyond Citigroup. The company was added to Bank of America’s US 1 List of top investment ideas. Furthermore, several firms, including RBC Capital and BMO Capital, reiterated Outperform ratings after a competing cystic fibrosis drug failed a mid-stage trial, a development noted by Meacham as part of the competitive backdrop.
Meacham’s note frames the Crinetics acquisition as a diversification play for Vertex, integrating a commercial endocrinology offering with ongoing development-stage assets. For investors evaluating biotech exposure, the combination of an immediate revenue-generating product and retained pipeline opportunities is highlighted as a primary reason for Vertex’s top ranking within Citi’s sector coverage.
Summary
Citigroup’s Geoff Meacham ranks Vertex Pharmaceuticals first among his biotech picks following the completion of the Crinetics acquisition. The deal introduces PALSONIFY as a commercial endocrinology product and preserves development programs such as atumelnant, supporting a broader therapeutic footprint that augments Vertex’s existing cystic fibrosis and other franchises. Citi keeps a Buy rating and a $585 price target, and expects the transaction to be accretive to non-GAAP operating income by 2029.
Key points
- Vertex completed the acquisition of Crinetics for $10 billion in equity, or $8.8 billion net of acquired cash, after receiving regulatory clearance and shareholder approval - impacting the biotech and pharmaceutical sectors.
- PALSONIFY provides immediate commercial revenue as the first once-daily oral therapy approved for acromegaly, with Citi forecasting $700 million in sales by 2030 - a development relevant to endocrinology and specialty drug markets.
- Atumelnant remains in phase 3 for congenital adrenal hyperplasia and phase 2 for Cushing’s syndrome, preserving clinical-stage upside and broadening Vertex’s therapeutic platforms beyond cystic fibrosis, hematology, pain, and renal.
Risks and uncertainties
- Timing of financial disclosure - full financial details are scheduled to be presented on Vertex’s third quarter 2026 earnings call on November 2; investors will need those details to fully assess transaction economics, affecting biotech investment decisions.
- Accretion timeline - Vertex expects the acquisition to be accretive to non-GAAP operating income in 2029, which leaves multi-year execution risk for integration and financial performance that could influence market valuations in the interim.
- Pipeline and competitive outcomes - atumelnant remains in clinical development across indications, and the competitive landscape in cystic fibrosis continues to shift after a competing CF drug failed a mid-stage trial; clinical and competitive results will materially affect sector dynamics.
Disclosure